Tower Research Capital LLC (Trc) Adc Therapeutics Sa Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 5,597 shares of ADCT stock, worth $9,626. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,597
Previous 4,646
20.47%
Holding current value
$9,626
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ADCT
# of Institutions
85Shares Held
55.3MCall Options Held
24.1KPut Options Held
44.7K-
Redmile Group, LLC San Francisco, CA15.7MShares$26.9 Million2.44% of portfolio
-
Prosight Management, LP Dallas, TX9.52MShares$16.4 Million5.62% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.97MShares$10.3 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.96MShares$6.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$6.11 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $134M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...